key: cord-0933582-ll0pr00x
authors: Melms, L. E.; Falk, E.; Schieffer, B.; Jerrentrup, A.; Wagner, U.; Matrood, S.; Schaefer, J. R.; Müller, T.; Hirsch, M.
title: Towards a COVID-19 symptom triad: The importance of symptom constellations in the SARS-CoV-2 pandemic
date: 2021-02-03
journal: nan
DOI: 10.1101/2021.02.01.21250537
sha: 4e3fa2c7999c1c7cd54bdbb3cef264df77090028
doc_id: 933582
cord_uid: ll0pr00x

Pandemic scenarios like SARS-Cov-2 require rapid information aggregation. In the age of eHealth and data-driven medicine, publicly available symptom tracking tools offer efficient and scalable means of collecting and analyzing large amounts of data. As a result, information gains can be communicated to front-line providers. We have developed such an application in less than a month and reached more than 500 thousand users within 48 hours. The dataset contains information on basic epidemiological parameters, symptoms, risk factors and details on previous exposure to a COVID-19 patient. Exploratory Data Analysis revealed different symptoms reported by users with confirmed contacts vs. no confirmed contacts. The symptom combination of anosmia, cough and fatigue was the most important feature to differentiate the groups, while single symptoms such as anosmia, cough or fatigue alone were not sufficient. A linear regression model from the literature using the same symptom combination as features was applied on all data. Predictions matched the regional distribution of confirmed cases closely across Germany, while also indicating that the number of cases in northern federal states might be higher than officially reported. In conclusion, we report that symptom combinations anosmia, fatigue and cough are most likely to indicate an acute SARS-CoV-2 infection.

In December 2019 cases of pneumonia of unknown etiology were reported in Wuhan, China 1 . The pathogenic agent, which was later identified as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250537 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. spread over the whole country and the rest of the world. On January 31, the World Health Organization held a press conference and declared the outbreak a Public Health Emergency of International Concern (PHEIC) 2 . On March 11, 2020 , the coronavirus outbreak was declared a global pandemic by the WHO 2 . Lockdown measures were introduced on March 22st in Germany 3 . Up to July 30, there has been more than 16 million confirmed cases worldwide.

The unprecedented speed and infectivity of such a pandemic requires novel information and communication structures for consolidating scientific knowledge [4] [5] [6] . So-called data crowdsourcing has been used as a warning and information system for waves of influenza since late 2000 [7] [8] [9] . This usually refers to applications that query flu-like symptoms at regular time intervals and issue warnings for affected areas by consolidating and analyzing the data. The advantage of these solutions lies in their cost-effective scalability and the resulting speed of data collection 9,10 , making them a crucial tool for the data-driven response of highly infectious diseases 11 . With the SARS-CoV-2 outbreak, many of these apps have been adapted or newly developed accordingly: In Switzerland "covidtracker.ch" 12 , in Spain "CoronaMadrid" 13 , in France "maladiecoronavirus.fr" 14 and in England the App "COVID Symptom Study" 15 are successfully used.

Currently, health care authorities primarily monitor the spreading dynamics of SARS-CoV-2 by the number of virus-specific positive reverse transcriptase polymerase chain reaction (RT-PCR) tests. However, the rapid transmission of SARS-CoV-2 has revealed weaknesses in current semi-digital monitoring practices of federally organized states like Germany, which heavily rely on decentralized reporting of laboratory tests. For an effective early warning system, however, daily updated data streams are of essential importance in order to be able to take effective measures quickly. Analysis of crowd-sourced clinical features and risk factors offers a promising opportunity for continuous prevalence monitoring in the population. In the future, both monitoring methods could perfectly complement each other in order to better understand the dynamics of infectious transmissions 6 .

Numerous studies have shown that the SARS-CoV-2-infection has diverse signs and symptoms [16] [17] [18] [19] , with fever, cough and fatigue being the most common at onset of illness [19] [20] [21] [22] [23] . However, recent studies suggest that only half the patients are febrile at the time of hospital admission 19, 22 . In addition, more attention is now drawn to formerly underestimated extrapulmonary symptoms and symptom constellations 24-28 : loss of smell (i.e. anosmia), for instance, varies greatly in COVID-19 patient (33 -68%) 29 but often was one of the first apparent symptoms 30 .

In Germany, the Robert Koch Institute (RKI) responsible for disease control and prevention, records loss of smell and taste as symptoms for COVID-19 cases since calendar week 17. According to current RKI recommendations,

patients are now also being tested for SARS-CoV-2, who show impairments of the sense of smell 31 . Already in . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint March, the British Society of ENT Physicians, ENT UK, wrote in a statement: "There is already good evidence from South Korea, China and Italy that significant numbers of patients with proven COVID-19 infection have developed anosmia/hyposmia" 32 . The British physicians called for people who noticed a loss of smell to voluntarily quarantine themselves. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also reported that a loss of smell has been observed in otherwise symptom-free SARS-CoV-2 positives and, as a consequence, developed a COVID-19 Anosmia Reporting Tool 33 . In a collaborative effort, the COPE consortium of UK-and US-based researches investigated a smartphone-based self-reported longitudinal and diverse COVID-19 survey data set (n = 805753) and found that the less common symptom anosmia in combination with the more established symptoms fever and cough were the strongest predictors of COVID-19 24 , complimenting recent scientific findings.

The symptom checking application COVID-Online was developed by the Institute of Artificial Intelligence (Philipps University Marburg) and is written in the Go programming language. The web app was accessible via a publicly accessible website covid-online.de. The questionnaire contained a total of 38 items, whereby 10 items appear only in relation to previous items (i.e. adaptive items).

Informed consent for scientific evaluation was provided by accepting the privacy policy (explicitly asked before submitting the questionnaire, see point 3.1 in the privacy policy). Users also had to confirm that they are at least 18 years old. Furthermore, the paragraph "I agree that COVID-Online may process and evaluate the data I have entered in a pseudonymised form" had to be explicitly agreed to as an opt-in checkbox.

The graphical user interface to answer the questions contained single choice, multiple choice and free text input fields. The questionnaire was divided into three segments, which were presented one after the other: first, basic epidemiological data such as gender, approximate age, approximate height, and approximate weight were collected. Then current symptoms (fever, body aches, cough, sniff, diarrhea, nausea, vomiting, throat pain, headache, loss of smell or taste, dyspnea, fatigue) were queried that could indicate COVID-19. Finally, users were prompted for individual risk factors such as smoking status and comorbidities (lung disease, diabetes, cardiovascular disease, stroke, tumor disease, chronic inflammatory disease, kidney disease, allergies), vaccination status (flu, measles) and their postal code. The complete survey items are available in the supplementary ( Table 1) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250537 doi: medRxiv preprint

The web app was launched on April 3rd. At this time, the new infections reached its peak in Germany and the population was in a phase of great uncertainty. Our main goal developing COVID-Online was patient care navigation by guiding the participant through the next steps in case of increased risk, and by this serving as a guidance system for regional patient management to enable an efficient allocation of resources in case of emergency.

All data was obtained from a database query (SQL) in the comma-separated values format (CSV) from the application servers. Program libraries Pandas, SciPy, Matplotlib, Seaborn and Jupyter were used for exploratory data analysis, data post-processing and plotting. We dropped users with missing or invalid postal codes.

Basic characteristics were analysed using descriptive statistics. Groups were formed based on the independent variables age, gender, comorbidities and confirmed contact to a COVID-19 patient. Chi-squared test and Cramer's V correlation were used for data analysis. For categorical variables, we report absolute numbers and percentages.

For continuous variables, we report averages ± standard deviation, unless otherwise stated. No imputation was made for missing data. All statistical tests were carried out with a significance level of α = 5%.

Previous work by Drew et al. has shown that symptom combinations are more suitable for distinguishing between COVID-19 positive and negative cases than single symptoms alone 34 . We investigated if the same applies to our dataset. Exploratory data analysis revealed that groups can be divided based on the question "I had confirmed contact to a COVID-19 case". The reason for a different reporting of symptoms of subjects with confirmed contact could be that these participants have a higher sensitivity to symptom inquiry due to fear of infection or that contact has led to a manifestation of the disease with corresponding presentation of symptoms. In the latter case, a higher overall level of infection is to be expected within the formed group. Lastly, we applied the generated linear model by Drew et al. including age, sex, loss of smell, fatigue, cough and loss of appetite to our data:

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250537 doi: medRxiv preprint + (0·44 x sex) + (1·75 x loss of smell and taste) + (0·31 x severe or significant persistent cough)

where the prediction was calculated as exp(x) / (1 + exp(x) with a threshold of 0·5 as suggested by Drew et al. 34 .

As loss of appetite was not queried by our questionnaire, it was set to true whenever a subject reported anosmia.

Clinical experience has shown that loss of appetite rarely occurs isolated and is rather a consequence of the loss of smell. To confirm our findings, we compared the frequencies of predicted and confirmed infections in a sevenday window geographically by districts and contrasted this with the distribution of the individual predictive symptoms fever, anosmia and cough.

The funding source by the Munch Foundation was not involved in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250537 doi: medRxiv preprint Exploratory Data Analysis revealed that the answer to the question whether if a previous contact with a confirmed case of a COVID patient occurred, changed the symptom frequency distribution between these groups.

A chi-square test of independence was performed to examine the relation between previous confirmed contact and individual symptoms sniff, cough, fatigue, body aches, headache, diarrhea, sore throat, nausea, dyspnea at rest, anosmia and fever. The relation between these variables was significant ( Table 2) :

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Therefore, patients were divided bases on the dichotomous question "I had contact to a confirmed case of COVID 19" into two groups. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint A, B, D, E, F: The district "Marburg-Biedenkopf" has been excluded from these charts as it contained too many records from internal tests carried out by associated personnel of COVID-Online and was also influenced by regional media reports. Unfortunately, due to the great time pressure in times of crisis, no test or staging instance could be installed for such purposes.

Unfortunately, there is not enough data on the number of total tests, because in Germany, according to the Infection Protection Act, only positive cases are reported to the health authorities. This makes it difficult to determine the actual test density per federal state and even more so per district. However, laboratories are invited to send the number of tests to the RKI. Since participation is voluntary, no statement can be made about the completeness of the tests (see Table 3 and 4):

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250537 doi: medRxiv preprint Data is from a sample of laboratories, not a complete survey of all tests in Germany. The coverage and representativeness of the data can greatly vary between the federal states. Unfortunately, the proportion of voluntary participation of the total is not known. Up to and including week 14/2020, 177 laboratories have registered for this RKI test laboratory interrogation or in one of the other transmitting networks. The data was derived from the Management Report on Coronavirus Disease (as of April 8, 2020) and the graphs contained therein. From these tables it can be seen that Bavaria and North Rhine-Westphalia have tested the most, both in terms of population and in absolute terms. Lower Saxony, Baden-Wuerttemberg, Schleswig-Holstein and Mecklenburg-Western Pomerania, on the other hand, tested least according to these data. However, it must be emphasised that this may also be due to a lower participation rate in data transmissions. If one assumes, however, that the participation density between the federal states would be approximately the same, more cases would probably have been measured in these states.

In contrast to other countries, preventive testing is not carried out in Germany to date, but only as an indication test on symptomatic patients and contact persons of such patients. Furthermore, the RKI recommends extending the indication for testing to nursing or care facilities and medical personnel. In the case of local outbreaks, mass testing is also carried out within a few days to contain the outbreak. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. is also considered, it can be assumed that the number of positive cases in the northern part of Germany is likely to be higher at the time of observation. In these cases, more test resources could be mobilized to initiate effective isolation and containment strategies for the spread in the future.

The near real-time analysis of symptom tracking applications might help to more accurately understand the spread and infectivity of infectious diseases such as SARS-CoV-2. In addition, risk factors can be collected and quantified in addition to symptoms. This is a decisive added value compared to the sole laboratory testing for an infectious disease, since persons at risk can be identified on the basis of the data and can be more quickly assigned to a potential therapy. The user numbers from Germany and England indicate a broad acceptance of such tools in pandemic scenarios 24, 34 . Symptom-tracking tools may thus play an important role in the control and containment of infectious diseases, alongside Sars-CoV-2, and provide significant added value for public health matters. Future implications are based on these tests and their accuracies, that the combination of both, adequate laboratory tests plus preventive screening such as COVID-Online, may predict future outbreaks and/or hint towards hotspot developments in clinically actionable windows.

It must be emphasized, though, that symptom screening and thereby symptom-based scoring systems will not likely reach a sufficient sensitivity for COVID-19 as asymptomatic carriage remains a problem. For instance, in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250537 doi: medRxiv preprint the Diamond Princess cruise ship study, it was estimated that a proportion of 17·9% among all infected cases were asymptomatic 36 . Asymptomatic patients further complicate the screening problem by the high risk of silent transmission. This implicates that the value of symptom inquiry for individual screening scenarios might be limited, but nevertheless offers crucial insights on a public health level when it comes to understanding the dynamics of spread, containment strategies and hot spot identification.

Our work has numerous limitations. One major limitation of our study is that we do not have data on confirmatory laboratory test results of the study participants. Because of this, we cannot extend and/or adopt the proposed model by Drew et al. by means of, for instance machine learning. Notably though, the same symptom combination was the most discriminative between the groups with and without confirmed contact, which suggests that the proposed combination might indeed achieve the highest specifity. In addition, we recognize that the data collected originates from a modern web application. Although a balanced gender and age distribution was achieved in the study population, it can be assumed that less technology-affine individuals are underrepresented in the study collective, which means that a contributor bias cannot be excluded. Thus, it cannot be ruled out that certain symptom constellations are more likely to be significant than others, which may be more common in underrepresented user groups. Furthermore, the nature of the collected data is self-reported. Data validity is therefore not checked and may contain false statements. Another limitation is that since users cannot create an account for reasons of data security and privacy, only snapshots of symptoms can be collected and cannot be tracked over time (i.e. longitudinal data). Also, our data and calculations are based on submissions of the questionnaire and do not strictly correlate with the number of individuals, as users can access the web app and submit the questionnaire multiple times. Because of this, we are only able to identify potential COVID-19 patients at the time of complete manifestation.

With the enormous advancements in technology we now have valuable digital tools that not only can keep up with the speed of the spread but also offer unique and actionable key insights for health care professionals. Our work confirms that the symptom combination of anosmia, fatigue and cough are indeed more specific for COVID-19 than single symptoms alone. Besides identifying potential hot spots that require more test resources, data on preexisting conditions and risk factors such as smoking are obtained, too. By identifying high risk patients with a high probability of a SARS-CoV-2 infection, this opens up the opportunity to take timely preventive measures. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250537 doi: medRxiv preprint suffering from anosmia, fever and cough should consider self-quarantine. Moreover, our approach demonstrates that crowd-sourced data represents an effective and scalable means for collecting population-based data for a datadriven public health response to infectious disease outbreaks in light of the COVID-19 pandemic. We could show that sophisticated and well-accepted real-time symptom reporting analytical platforms can be developed rapidly, even with limited personnel resources. We also demonstrate the potential of crowdsourced data to complement traditional public health surveillance methods, primarily through providing fast, on-demand insights and increased information coverage. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250537 doi: medRxiv preprint

A pneumonia outbreak associated with a new coronavirus of probable bat origin

COVID-19) Situation Reports

Besprechung der Bundeskanzlerin mit den Regierungschefinnen und Regierungschefs der Länder

Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study

Using "outbreak science" to strengthen the use of models during epidemics

Diagnosing COVID-19: The Disease and Tools for Detection

Influenzanet: Citizens Among 10 Countries Collaborating to Monitor Influenza in Europe

Participatory Syndromic Surveillance of Influenza in Europe

Flu Near You: Crowdsourced Symptom Reporting Spanning 2 Influenza Seasons

Why We Need Crowdsourced Data in Infectious Disease Surveillance

Digital Disease Detection -Harnessing the Web for Public Health Surveillance

COVID-19 Tracking Schweiz

COVID Symptom Study -Help slow the spread of COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A novel coronavirus outbreak of global health concern

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis

COVID-19 pandemic-a focused review for clinicians

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Real-time tracking of self-reported symptoms to predict potential COVID-19

Sinonasal pathophysiology of SARS-CoV-2 and COVID-19: A systematic review of the current evidence

New loss of smell and taste: Uncommon symptoms in COVID-19 patients on

Extrapulmonary manifestations of COVID-19

Epidemiological Observations on the Association Between Anosmia and COVID-19 Infection: Analysis of Data From a Self-Assessment Web Application

COVID-19 and anosmia: A review based on up-to-date knowledge

Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection

COVID-19 Verdacht: Testkriterien und Maßnahmen Orientierungshilfe für Ärztinnen und Ärzte

Loss of sense of smell as marker of COVID-19 infection

Rapid implementation of mobile technology for real-time epidemiology of COVID-19

Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network -United States

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

The authors thank all the participants, coordinators, and administrators for their support and help during the data acquisition. This work has received financial support from the Münch Foundation. The founding source did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of 

Am. J. Otolaryngol. 41, 102581 (2020). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted February 3, 2021. 

The authors have no conflict of interest to declare.

All correspondences and requests for materials should be addressed to L.M.

The survey data analyzed in study is not publicly available due to information that could compromise patient privacy/consent. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250537 doi: medRxiv preprint